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Abstract: Nuts (tree nuts and peanuts) are nutrient dense foods with complex matrices rich 
in unsaturated fatty and other bioactive compounds: high-quality vegetable protein, fiber, 
minerals, tocopherols, phytosterols, and phenolic compounds. By virtue of their unique 
composition, nuts are likely to beneficially impact health outcomes. Epidemiologic studies 
have associated nut consumption with a reduced incidence of coronary heart disease and 
gallstones  in  both  genders  and  diabetes  in  women.  Limited  evidence  also  suggests 
beneficial  effects  on  hypertension,  cancer,  and  inflammation.  Interventional  studies 
consistently show that nut intake has a cholesterol-lowering effect, even in the context of 
healthy  diets,  and  there  is  emerging  evidence  of  beneficial  effects  on  oxidative  stress, 
inflammation, and vascular reactivity. Blood pressure, visceral adiposity and the metabolic 
syndrome also appear to be positively influenced by nut consumption. Thus it is clear that 
nuts  have  a  beneficial  impact  on  many  cardiovascular  risk  factors.  Contrary  to 
expectations, epidemiologic studies and clinical trials suggest that regular nut consumption 
is unlikely to contribute to obesity and may even help in weight loss. Safety concerns are 
limited  to  the  infrequent  occurrence  of  nut  allergy  in  children.  In  conclusion,  nuts  are 
nutrient rich foods with wide-ranging cardiovascular and metabolic benefits, which can be 
readily incorporated into healthy diets. 
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1. Introduction 
Extensive research has been carried out on nuts and health outcomes during the last two decades 
since publication of a report from the pioneering Adventist Health Study showing an association of nut 
consumption with a lower risk of coronary heart disease (CHD) in 1992 [1], shortly followed by the 
seminal clinical trial of Sabaté et al. [2] demonstrating that a diet enriched with walnuts reduced serum 
cholesterol  levels  compared  to  a  standard  healthy  diet.  The  interested  reader  will  find  complete 
information  regarding  research  published  up  to  2005  on  nuts  and  health  outcomes  in  a  recent 
monograph [3] and up to 2007 in the proceedings of a Symposium on Nuts and Health held at the U.S. 
Department of Agriculture Research Laboratory in the University of California at Davis [4].  
By  definition,  tree  nuts  are  dry  fruits  with  one  seed  in  which  the  ovary  wall  becomes  hard  at 
maturity.  The  most  popular  edible  tree  nuts  are  almonds  (Prunus  amigdalis),  hazelnuts  (Corylus 
avellana), walnuts (Juglans regia), and pistachios (Pistachia vera). Other common edible nuts are pine 
nuts  (Pinus  pinea),  cashews  (Anacardium  occidentale),  pecans  (Carya  illinoiensis),  macadamias 
(Macadamia  integrifolia),  and  Brazil  nuts  (Bertholletia  excelsa).  The  consumer  definition  also 
includes  peanuts  (Arachis  hypogea),  which  botanically  are  groundnuts  or  legumes  but  are  widely 
identified as part of the nuts food group. In addition, peanuts have a similar nutrient profile to tree 
nuts [5,6]. Although chestnuts (Castanea sativa) are tree nuts as well, they are different from all other 
common nuts because of being starchier and having a different nutrient profile. For the purpose of this 
review, the term “nuts” includes all common tree nuts [with the exception of chestnuts] plus peanuts. 
Nuts, seeds and pulses are all nutrient dense foods and have been a regular constituent of mankind’s 
diet since pre-agricultural times [7]. In Western countries nuts are consumed as snacks, desserts or part 
of a meal, and are eaten whole (fresh or roasted), in spreads (peanut butter, almond paste), as oils or 
hidden in commercial products, mixed dishes, sauces, pastries, ice creams and baked goods. In the last 
century, nut consumption in most industrialized nations followed a downward trend to become only a 
marginal  source  of  energy  in  the  daily  diet,  except  for  vegetarians  and  other  health-conscious 
populations, such as Seventh Day Adventists [8,9]. However, nut consumption has increased in recent 
times in Western countries following both the inclusion of this food group in many guidelines for 
healthy eating and wide media coverage of recent evidence connecting nut consumption to a wide 
range of health benefits. Thus, nuts have been proposed as an important component of optimal diets for 
the prevention of CHD by leading experts in the field [10] and, in the summer of 2003, the US Food 
and Drug Administration issued a health claim for nuts because of the link between nut consumption 
and a reduced risk of both CHD and intermediate biomarkers, such as blood cholesterol  [11]. Since 
then, nuts have become an indispensable component of healthy diets [12,13] and are included in the 
American Heart Association dietary metrics for defining ideal cardiovascular health in their recent 
report on setting goals for health promotion and disease reduction for 2020 [14].  
The  scientific  evidence  behind  the  proposal  of  nuts  as  cardio-protective  foods  stem  from  both 
epidemiological observations suggesting a consistent inverse association between the frequency of nut 
intake  and  development  of  CHD  [reviewed  in  13,15,16]  and  numerous  short-term  clinical  trials 
showing  beneficial  effects  of  nut  intake  on  the  lipid  profile  [reviewed  in  13,17-20]  and  other 
intermediate  markers  of  CHD  [reviewed  in  13,20-22].  The  mechanism  for  these  salutary  effects 
probably lies in the synergistic interaction of the many bioactive constituents of nuts, which may all Nutrients 2010, 2                                       
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favorably influence human physiology. Thus, nuts contain high amounts of vegetable protein [5] and 
fat, mostly unsaturated fatty acids [6]. They are also dense in a variety of other nutrients and provide 
dietary  fiber  [23],  vitamins  (e.g.,  folic  acid,  niacin,  tocopherols,  and  vitamin  B6),  minerals  (e.g., 
calcium, magnesium, potassium) and many other bioactive constituents such as phytosterols [24] and 
phenolic compounds [25]. 
Contrary to expectations due to the high energy density of nuts, evidence from both epidemiological 
studies and clinical trials suggests that their regular consumption neither contributes to obesity nor 
increases the risk of developing diabetes, as reviewed [13,16,26,27]. The present review summarizes 
current knowledge on the expanding topic of nuts and health outcomes. First an outline of the unique 
nutrient content of nuts is necessary in order to better understand their health effects. 
2. Nutrient Content of Nuts 
Nuts are clearly nutrient dense foods. With the exception of chestnuts, which contain little fat, nuts 
have a high total fat content, ranging from 46% in cashews and pistachios to 76% in macadamia nuts, 
and they provide 20 to 30 kJ/g (Table 1). Thus, nuts are one of the natural plant foods richest in fat 
after vegetable oils. However, the fatty acid composition of nuts is beneficial because the saturated 
fatty  acid  (SFA)  content  is  low  (4–16%)  and  nearly  half  of  the  total  fat  content  is  made  up  of 
unsaturated fat, monounsaturated fatty acids MUFA (oleic acid) in most nuts, similar proportions of 
MUFA and polyunsaturated fatty acids (PUFA), mostly linoleic acid, in Brazil nuts, a predominance of 
PUFA over MUFA in pine nuts, and mostly PUFA, both linoleic acid and α-linolenic acid (ALA), the 
plant omega-3 fatty acid, in walnuts [6]. With regard to walnuts, it must be underlined that they are a 
whole  food  with  the  highest  content  in  ALA  of  all  edible  plants  [28].  As  discussed  below,  the 
particular  lipid  profile  of  nuts  in  general  and  walnuts  in  particular  is  likely  to  be  an  important 
contributor to the beneficial health effects of frequent nut consumption. 
Nuts are also rich sources of other bioactive macronutrients that have the potential to beneficially 
affect metabolic and cardiovascular outcomes. They are an excellent source of protein (approximately 
25% of energy) and often have a high content of L-arginine [5]. As this amino acid is the precursor of 
the endogenous vasodilator, nitric oxide (NO) [29], nut intake might help improve vascular reactivity, 
as discussed below. Nuts also are a good source of dietary fiber, which ranges from 4 to 11 g per 100 g 
(Table 1), and in standard servings provide 5–10% of daily fiber requirements [23]. 
Table 1. Average nutrient composition of nuts (per 100 g). 
 Nuts  Energy 
(kJ) 
 Fat 
(g) 
 SFA 
(g) 
MUFA 
(g) 
PUFA 
(g) 
LA 
(g) 
ALA 
(g) 
Protein 
(g) 
Fiber 
(g) 
Folate 
(µg) 
PS 
(mg) 
Almonds  2418  50.6  3.9  32.2  12.2  12.2  0.00  21.3  8.8  29  120 
Brazil nuts 
(dried) 
2743  66.4  15.1  24.5  20.6  20.5  0.05  14.3  8.5  22  NR 
Cashews  2314  46.4  9.2  27.3  7.8  7.7  0.15  18.2  5.9  25  158 
Hazelnuts  2629  60.8  4.5  45.7  7.9  7.8  0.09  15.0  10.4  113  96 Nutrients 2010, 2                                       
 
 
655
Table 1. Cont. 
Macadamia 
nuts 
3004  75.8  12.1  58.9  1.5  1.3  0.21  7.9  6.0  11  116 
Peanuts  2220  49.2  6.8  24.4  15.6  15.6  0.00  25.8  8.5  145  220 
Pecans  2889  72.0  6.2  40.8  21.6  20.6  1.00  9.2  8.4  22  102 
Pine nuts 
(dried) 
2816  68.4  4.9  18.8  34.1  33.2  0.16  13.7  3.7  34  141 
Pistachios  2332  44.4  5.4  23.3  13.5  13.2  0.25  20.6  9.0  51  214 
Walnuts  2738  65.2  6.1  8.9  47.2  38.1  9.08  15.2  6.4  98  72 
Data for raw nuts, except where specified. SFA, saturated fatty acids; MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids; LA, linoleic acid; ALA, α-linolenic acid; PS, plant 
sterols; NR, not reported. 
Source: US Department of Agriculture Nutrient Data Base at: http://www.nal.usda.gov/fnic/ 
cgi-bin/nut_search.pl (Accessed on 26 April 2010). 
 
Among the constituents of nuts there are significant amounts of essential micronutrients that are 
associated with an improved health status when consumed at doses beyond those necessary to prevent 
deficiency states. Nuts contain sizeable amounts of folate (Table 1) [24], a B-vitamin necessary for 
normal  cellular  function  that  plays  an  important  role  in  detoxifying  homocysteine,  a  
sulfur-containing amino acid with atherothrombotic properties that accumulates in plasma when folate 
status is subnormal [30]. Nuts are also rich sources of antioxidant vitamins (e.g., tocopherols) and 
phenolic compounds, necessary to protect the germ from oxidative stress and preserve the reproductive 
potential of the seed, but also bioavailable after consumption and capable of providing a significant 
antioxidant load [25]. Almonds in particular are especially rich in α-tocopherol, while walnuts contain 
significant  amounts  of  its  isomer  γ-tocopherol,  which  has  been  investigated  much  less  than  α-
tocopherol, but is increasingly recognized as a relevant antiatherogenic molecule [31]. Remarkably, in 
all  nuts  most  of  the  antioxidants  are  located  in  the  pellicle  or  outer  soft  shell,  as  shown  for  
almonds [32,33] and peanuts [34], and 50% or more of them are lost when the skin is removed [25]. 
Bleaching of nuts when the hard shells are cracked, as it occurs naturally in pistachios, also destroys 
most of the antioxidants [35]. Interestingly, roasting of almonds preserves the phenolic compounds 
better  than  blanching  [36].  These  facts,  rarely  taken  into  consideration  in  prior  studies  with  nuts, 
should not be overlooked when giving advice on nut intake in healthy diets. Walnuts are an exception 
because they are almost always consumed as a raw, unpeeled product. 
Nuts are cholesterol-free, but their fatty fraction contains sizeable amounts of chemically related 
noncholesterol sterols belonging to a heterogeneous group of compounds known as plant sterols or 
phytosterols (Table 1) [24]. They are non-nutritive components of all plants that play an important 
structural role in membranes, where they serve to stabilize phospholipid bilayers just as cholesterol 
does in animal cell membranes [37]. Phytosterols interfere with cholesterol absorption and thus help Nutrients 2010, 2                                       
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lower blood cholesterol when present in sufficient amounts in the intestinal lumen. The mechanism of 
action of phytosterols has been linked to their hydrophobicity, which is higher than cholesterol because 
of  a  bulkier  hydrocarbon  molecule  and  entails  a  higher  affinity  for  micelles  than  has  cholesterol. 
Consequently, cholesterol is displaced from micelles and the amount available for absorption is limited [36]. 
In all probability the phytosterol content of nuts contributes to their cholesterol-lowering effect (see 
below). 
Compared to other common foods, nuts have an optimal nutritional density with respect to healthy 
minerals,  such  as  calcium,  magnesium,  and  potassium.  Like  that  of  most  vegetables,  the  sodium 
content of raw or roasted but otherwise unprocessed nuts is very low, ranging from undetectable in 
hazelnuts  to  18  mg/100  g  in  peanuts  (Table  2)  [24].  A  high  intake  of  calcium,  magnesium  and 
potassium,  together  with  a  low  sodium  intake,  is  associated  with  protection  against  bone 
demineralization,  arterial  hypertension,  insulin  resistance,  and  overall  cardiovascular  risk  [39]. 
Obviously,  the  advantage  of  the  low  sodium  content  of  nuts  is  lost  if  they  are  consumed  as  a  
salted product. 
In  summary,  the  macronutrient,  micronutrient  and  non-nutrient  components  of  nuts  shown  in 
Table 1 and Table 2 have all been documented to contribute to a reduced risk of CHD and related 
metabolic disturbances. For these reasons, whole raw, unpeeled and otherwise unprocessed nuts may 
be considered as natural health capsules, where the whole is always better than the parts [40].   
Table 2. Calcium, magnesium, sodium and potassium content of nuts and other foods in 
mg/100 g of edible portion. 
Nuts  Calcium  Magnesium  Sodium  Potassium 
Almonds  248  275  1  728 
Brazil nuts  160  376  3  659 
Cashew nuts  37  292  12  660 
Hazelnuts  114  163  0  680 
Macadamia nuts  85  130  5  368 
Peanuts  92  168  18  705 
Pecans  70  121  0  410 
Pine nuts  16  251  2  597 
Pistachios  107  121  1  1025 
Walnuts  98  158  2  441 Nutrients 2010, 2                                       
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Table 2. Cont. 
Other foods         
Apples (with skin)  6  5  1  107 
Bananas  5  27  1  358 
Beans (white, cooked)  90  63  6  561 
Broccoli (cooked)  40  21  41  293 
Cheese (cheddar)  721  28  621  98 
Chickpeas (cooked)  49  48  7  291 
Ham  24  22  1304  287 
Lettuce (romaine)  33  14  8  247 
Milk  113  10  40  143 
Rice (white, cooked)  10  38  1  35 
Sardines (canned in oil)  382  39  505  397 
Spinach (cooked)  136  87  70  466 
Tomato  10  11  5  237 
Veal (cooked)  22  26  87  325 
Wheat bread  72  86  527  252 
Source: US Department of Agriculture Nutrient Data Base at: http://www.nal.usda.gov/fnic/ 
cgi-bin/nut_search.pl (Accessed on 26 April 2010). 
3. Epidemiological Studies of Nut Consumption and Health Outcomes 
3.1. Nut Consumption and CHD Risk 
Four prospective studies conducted in the US have reported a beneficial effect of nut consumption 
on CHD incidence after follow-up ranging from six to 18 years of large cohorts of previously healthy 
subjects [1,41-43]. A pooled analysis of these studies shows that subjects in the highest intake group 
for  nut  consumption  had  a  37%  reduction  in  multivariable-adjusted  risk  of  fatal  CHD  [15].  The 
combined relative risk for total CHD mortality derived from the comparison of rates between the 
highest and lowest frequency of nut intake in all four studies was 0.63 [95% confidence interval [CI], 
0.51 to 0.83]. Importantly, a dose-response relationship between nut consumption and reduced CHD 
mortality rates was reported for all four studies, strengthening the causal link (Figure 1). Of particular 
note are the results of the Physicians’ Health Study [43], where the inverse association between nut 
consumption  and  total  CHD  mortality  was  primarily  due  to  a  reduction  in  sudden  cardiac  death. 
Compared with men who rarely or never consumed nuts, those who consumed nuts two or more times 
per week had a 47% reduced risk of sudden cardiac death (relative risk, 0.53; CI, 0.30 to 0.92). 
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Figure  1.  Results  of  prospective  studies  of  nut  consumption  and  risk  of  death  from 
coronary heart disease. 
 
 
In the Nurses’ Health Study [41], nut intake could be subdivided between all tree nuts and peanuts 
and peanut butter. Consumption of peanut products was also associated with a decreased relative risk 
of CHD. Subjects who consumed peanuts two or more times per week had a relative risk of CHD of 
0.66 (CI, 0.46 to 0.94), while for other nuts the relative risk for consumption of two or more times per 
week was 0.79 (CI, 0.50 to 1.25). A recent report of the same study concerning a subgroup of 6309 
women  with  type-2  diabetes  at  baseline  shows  similar  findings,  as  consumption  of  at  least  five 
servings  per  week  of  nuts  or  peanut  butter  (serving  size,  28  g  [1  ounce]  for  nuts  and  16  g  [1 
tablespoon] for peanut butter) was significantly associated with a lower risk of cardiovascular disease, 
with a relative risk of 0.56 (CI, 0.36 to 0.89) [44]. 
It must be underlined that in all these studies [1,41-44] the protective effect of nut consumption on 
total CHD or sudden cardiac death was independent of gender, age, body mass index, alcohol use, 
other  nutritional  characteristics  or  presence  of  cardiovascular  risk  factors.  The  dose-relationship 
between nut intake and incident CHD translates into an average 8.3 reduction for each weekly serving 
of nuts [15]. The consistency of findings in all studies points to a causal association between nut 
consumption and reduced CHD, indicating that nuts possibly are one of the most cardioprotective 
foods in the habitual diet. 
Since inflammation is a key process in atherogenesis, one mechanism by which nut consumption 
may decrease CHD risk is by improving inflammatory status, which can be ascertained from levels of 
circulating inflammatory markers. Three cross-sectional studies have investigated nut consumption in 
relation  to  circulating  inflammatory  biomarkers  [45-47].  In  an  analysis  of  data  from  nearly  6000 
participants in the Multi-Ethnic Study of Atherosclerosis (MESA) [45], consumption of nuts and seeds 
was inversely associated with levels of inflammatory markers, C-reactive protein (CRP), interleukin-6 
(IL-6) and fibrinogen. Another study of 987 diabetic women from the prospective Nurses’ Health 
Study  [46]  showed  a  direct  association  between  nut  consumption  and  increased  plasma  levels  of 
adiponectin,  an  adipose  tissue-secreted  cytokine  with  antiinflammatory  and  antiatherosclerotic 
properties. The third study was carried out in 772 older subjects at high risk for CHD living in Spain Nutrients 2010, 2                                       
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for the purpose of assessing adherence to the Mediterranean dietary pattern and its food components in 
relation  to  levels  of  soluble  inflammatory  markers.  Adjusted  mean  serum  levels  of  intercellular 
adhesion molecule-1 (ICAM-1), but not those of CRP or IL-6, decreased across increasing tertiles of 
nut consumption [47]. Thus, increasing epidemiologic evidence links frequent consumption of nuts to 
a reduced inflammatory status, which might help explain their cardio protective properties. 
3.2. Nut Consumption and Risk of Type-2 Diabetes 
In addition to cardiac outcomes, the Nurses’ Health Study also ascertained the incidence of type-2 
diabetes, a major risk factor for CHD, by frequency of nut and peanut butter intake during a 16-year 
follow-up  [48].  Nut  consumption  was  inversely  associated  with  risk  of  type-2  diabetes  after 
multivariate  adjustment  for  traditional  risk  factors,  with  relative  risks  across  categories  of  nut 
consumption (never/almost never, <once/week, 1-4 times/week, and >4 times/week) for a 28 g serving 
of 1.0, 0.92 (CI, 0.85 to 1.00), 0.84 (CI, 0.76 to 0.93), and 0.73 (CI, 0.60 to 0.89). Considering only 
lean women (BMI< 25 kg/m
2), a 45% risk reduction was observed in those consuming nuts five times 
or more per week. Consumption of peanut butter was also inversely associated with type-2 diabetes 
with an adjusted relative risk of 0.79 (CI, 0.68 to 0.91) in women consuming peanut butter more than 
four times a week (equivalent to≥15 ounces of peanuts per week) compared with those who never or 
almost never ate peanut butter.  
However, in the Iowa Women’s Health Study [49] the association between nut consumption and 
diabetes risk was less clear. In the 11 years of follow up, the postmenopausal women who ate nuts 
often had no reduced risk of diabetes compared to those who ate nuts occasionally after adjusting for 
multiple confounders. These negative findings might have been due to over adjustment for nutrients 
that mediate in part the protective effect of nuts, such as fiber and unsaturated fatty acids, because 
when adjusting for age only a significant 18% reduction in relative risk was observed between the 
highest and lowest categories of peanut butter consumption. To ascertain whether menopausal status 
influenced the association between nut consumption and diabetes risk, in response to the analysis of 
the Iowa Women’s Health Study authors of the Nurse’s Health Study report performed additional 
analysis stratifying by menopausal status, and the inverse association of nut consumption and diabetes 
risk changed little. Among premenopausal women the multivariate relative risk was 0.67 (CI, 0.46 to 
0.97) comparing those who ate nuts five times or more times a week with those who never or almost 
never ate nuts. Among postmenopausal women the corresponding relative risk was similar at 0.73 (CI, 
0.57 to 0.95) [49]. A subsequent report from a Chinese cohort of nearly 64,000 women followed up for 
4.6 years also suggests a protective effect of nuts on diabetes risk [50]. This study showed an adjusted 
20% risk reduction between the lowest quintile (0.1 g) and upper quintile (3.1 g) of daily peanut 
consumption.  
At  odds  with  the  findings  in  women,  a  recent  report  from  the  Physicians’  Health  Study  [51] 
suggests no protective effect of nut consumption on diabetes risk in men. In this study 20,224 male 
participants were followed for an average of 19  years. Adjusted hazard ratios for development of 
diabetes ranged from 1.06 (CI, 0.93 to 1.20) for men consuming less than one serving of nuts per week 
to 0.87 (CI, 0.61 to 1.24) for those eating at least a daily serving of nuts, and the results were similar in 
lean or overweight/obese participants. Figure 2 illustrates the findings of the main prospective studies 
relating nut consumption to the risk of developing type-2 diabetes. In summary, regular consumption Nutrients 2010, 2                                       
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of nuts is clearly beneficial for CHD risk, but confirmation of any protective role on diabetes risk must 
await further studies. 
Figure 2. Results of prospective studies of nut consumption and risk of diabetes. The two 
US studies considered the frequency of consumption of all nuts, including peanuts, while 
the Chinese study considered exclusively quintiles of peanut consumption in grams/day. 
 
 
3.3. Nut Consumption and other Health Outcomes 
Two prospective studies have assessed the frequency of nut consumption in relation to incident 
hypertension, with discordant results [52,53]. In a cohort of 15,966 participants in the Physicians’ 
Health Study [52] who were free of hypertension at baseline and had 237,585 person-years of follow 
up, adjusted hazard ratios for hypertension ranged from 0.97 (CI, 0.91 to 1.03) for nut consumption 
1-2 times per month to 0.82 (CI, 0.71 to 0.94) for nut consumption of seven or more times per week. In 
a  secondary  analysis  stratified  by  BMI,  there  was  an  inverse  relationship  between  nut  intake  and 
hypertension in lean subjects but not in those who were overweight or obese at baseline. These results 
must be taken with caution, however, because salt intake and changes in weight, two major factors that 
influence the risk of hypertension, were not accounted for in this study. The second study, which 
involved  9919  Spanish  university  graduates  followed-up  for  a  median  of  4.3  years  in  the  SUN 
cohort [53],  found  no  association  between  nut  consumption  and  incidence  of  hypertension  after 
adjusting for several confounders, including exposure to salt and weight changes during follow-up. 
The hazard ratio for the highest versus lowest nut consumption category was 0.77 (CI, 0.46 to 1.30) in 
this relatively young sample of well educated adults at little baseline risk for hypertension, thus a 
larger sample and longer duration of follow-up might have provided a better level of evidence. In 
summary, limited epidemiologic data provide only circumstantial evidence for a protective effect of 
nut consumption on development of hypertension. The fact that nuts are often eaten with salt from Nutrients 2010, 2                                       
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snack  packs  is  an  added  source  of  confusion  in  the  relationship  between  nut  consumption  and 
hypertension. 
The incidence of two major complications of hypertension, stroke and heart failure, was unrelated 
to  the  frequency  of  nut  consumption  in  recent  reports  from  the  prospective  Physicians’  Health  
Study [54,55]. Regarding stroke, while no association with total or ischemic stroke was observed, there 
was a suggestive non-linear relation between nut intake and hemorrhagic stroke: compared to subjects 
who did not consume nuts, adjusted hazard ratios for hemorrhagic stroke for subjects consuming nuts 
<1, 1, 2–4, 5–6, and 7 or more times per week were 1.13 (CI, 0.78 to 1.62), 1.05 (CI, 0.70 to 1.58), 
0.49 (CI, 0.27 to 0.89), 1.50 (CI, 0.79 to 2.84), and 1.84 (CI, 0.95 to 3.57), respectively (p for quadratic 
trend  0.12)  [50].  However,  there  were  a  limited  number  of  hemorrhagic  strokes  in  the  highest 
categories of nut consumption, thus further studies are clearly warranted to confirm or discard this 
improbable adverse effect of nuts. 
Some bioactive constituents of nuts, such as tocopherols, phytosterols, folic acid, selenium, and 
magnesium, are purported to have antioxidant, antiinflammatory or anticarcinogenetic properties [24], 
a reason why a protective effect of nut consumption on cancer risk might be hypothesized [56]. Old 
epidemiological  evidence  of  the  role  of  nut  consumption  on  cancer  incidence  was  
inconclusive  [57-59].  More  recent  reports  support  a  preventive  role,  although  limited  to  
women [56-59]. A small case-control study in Greek women [60] suggests that a diet rich in nuts, 
seeds and pulses reduces the risk of endometrial cancer by 27% compared to infrequent consumption 
of such foods. Results from the large EPIC study [61] showed no relation between higher intake of 
nuts and seeds and risk of colorectal cancers in the whole cohort or in men alone, but an inverse 
association was detected in women between the highest quintile of nut consumption (>6.2 g/day) and 
the lowest quintile (non-consumers), with an adjusted odds ratio of 0.69 (CI, 0.50 to 0.95). A gender 
discrepancy in the risk of colorectal cancer associated with peanut consumption was also reported from 
a population-based cohort study of approximately 24,000 people in Taiwan [62]. This study showed 
that women consuming peanuts had a remarkable risk reduction of 58% compared to non-consumers. 
However, the protective effect was not observed in men. A small clinical study in men at risk for 
prostate cancer showed increased serum γ-tocopherol and a trend towards an increase in the ratio of 
free prostate specific antigen (PSA): total PSA after eight weeks of a diet supplemented with 75 g 
walnuts per day compared with a control diet [63]. Two recent experimental studies using human 
cancer cell lines [64] and a mice model of human breast cancer [65] suggest an antiproliferative effect 
of walnuts. Clearly, more research is necessary on the important topic of nuts and cancer. 
Again because of the richness of nuts in bioactive components, particularly unsaturated fatty acids, 
fiber, and minerals, a protective effect of nut intake on gallstone disease is biologically plausible. Two 
separate studies by the same authors, each on different populations, examined the relationship between 
frequency of nut intake and gallstone disease risk. After following 80,718 women for 20 years, the 
Nurses’ Health Study [66] showed that frequent nut consumers (≥5/week) had a 25% reduced risk of 
cholecystectomy compared to non-consumers. Similar findings were observed among nearly 43,000 
men in the Health Professional’s Follow-up study [67]. During 457,305 person-years of follow-up, 
men who consumed 5 or more servings of nuts per week showed a risk of developing clinical gallstone 
disease that was 30% lower compared to those who rarely or never ate nuts. The results of the two Nutrients 2010, 2                                       
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studies  suggest  that  frequent  nut  consumption  is  equally  protective  of  gallstone  disease  in  men  
and women. 
Finally, patients with diverticular disease of the colon are frequently advised to avoid eating nuts 
and  seeds  to  reduce  the  risk  of  complications  but  there  is  little  evidence  to  support  this 
recommendation,  a  reason  why  investigators  from  the  Health  Professionals  Follow-up  Study  [68] 
evaluated the frequency of nut consumption in relation to new diagnoses of diverticular disease and its 
complications during 18 years of follow-up in 47,228 men. The results showed an inverse association 
between nut consumption and the risk of diverticulitis, with a multivariate hazard ratio for men with 
the  highest  intake  compared  with  those  with  the  lowest  intake  of  0.80  (CI,  0.63  to  1.01).  No 
associations  were  seen  between  nut  consumption  and  diverticular  bleeding  or  uncomplicated 
diverticulosis.  Clearly  there  are  no  reasons  to  recommend  avoiding  nuts  to  prevent  
diverticular complications. 
4. Nut Feeding Trials with Outcomes on Cardiovascular Risk Factors 
The epidemiologic evidence reporting benefits of nut consumption on CHD risk was the impetus for 
clinical studies designed to assess the effects on cardiovascular risk factors and begin to understand the 
underlying mechanisms that explained the observational data. Most clinical studies with nuts have 
been short-term and have compared diets supplemented with nuts with control diets for outcomes on 
blood lipid changes in healthy subjects or patients with moderate hypercholesterolemia. There have 
been fewer studies with nuts in patients with obesity, the metabolic syndrome, or type-2 diabetes 
investigating insulin sensitivity or glycemic control besides the lipid profile. More recent clinical trials 
have dealt with intermediate risk markers, such as blood pressure, oxidation biomarkers, antioxidant 
defenses and oxidative modification of lipids or DNA, and inflammation status. Some studies have 
focused on the relevant question of whether unrestricted nut intake leads to weight changes. Long-term 
studies targeting effects of nut consumption on metabolic syndrome, diabetes, CHD events and risk for 
chronic degenerative diseases are underway. 
4.1. Effects of Nuts on the Lipid Profile 
The first clinical trial using nuts was the Loma Linda University walnut study, published in 1993 [2]. 
In this landmark study, a cholesterol-lowering diet that provided 20% of energy from walnuts and 31% 
of energy from fat, of which 6% came from SFA and 16% from PUFA, was compared to a standard 
Step-I diet that provided 30% of energy from fat, of which 10% was from SFA and 10% from PUFA. 
Total cholesterol and LDL cholesterol decreased significantly by 12% and 18%, respectively in the 
healthy subjects studied. Since then, over 40 clinical studies have been conducted assessing the effects 
of  nut-enriched  diets  versus  isoenergetic,  usually  healthy  comparator  diets,  on  serum  lipids  and 
lipoproteins, as reviewed up to December 2004 in a pooled analysis of 25 intervention trials using 
different  nut  types  [69]  and  through  May  2008  in  a  meta-analysis  of  13  feeding  studies  with  
walnuts [70]. 
The nuts most frequently studied have been almonds and walnuts. Some feeding trials used peanuts, 
pecans, macadamia nuts, hazelnuts, pistachios, cashews, and Brazil nuts. To date there have been no 
clinical studies with pine nuts.  In the feeding trials the nut-supplemented diets were compared to Nutrients 2010, 2                                       
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various control diets: low in total fat and high in carbohydrate; high in SFA; a Mediterranean diet; the 
Japanese diet; or subjects’ usual diet. Although the degree of dietary control was variable, ranging 
from being tightly controlled (i.e., all foods provided by the investigators) to simply providing dietary 
advice to free-living participants eating on their own, the results have been consistent in showing a 
cholesterol-lowering effect of regular nut intake, usually without any significant effect on triglycerides 
or HDL cholesterol [2,13,17-20,69,70].  
Recently  the  findings  of  a  pooled  analysis  of  1,284  observations  contributed  by  583  unique 
participants from 25 clinical studies performed with different nuts, including peanuts, and conducted in 
seven  different  countries have  been  reported  [69].  The  results  show  a  dose-response  cholesterol-
lowering effect and indicate that, for an average daily intake of 67 g of nuts (roughly equivalent to 
20%  of  energy),  the  mean  estimated  reductions  of  total  cholesterol  and  LDL-cholesterol  were  11 
mg/dL (5%) and 10 mg/dL (7%), respectively. Nuts had no significant effect on HDL-cholesterol or 
triglycerides,  except  in  participants  with  serum  triglycerides  >150  mg/dL,  in  whom  a  significant  
10.2 mg/dL reduction was observed. Importantly, the lipid effects of nuts were dose-related, similar by 
gender and across all age groups, and independent of the type of nut tested. The statistical power of 
this pooled analysis also allowed detection of differential responses by baseline LDL-cholesterol level 
and BMI. The estimated cholesterol lowering effect of nuts was greater for participants with higher 
initial values of LDL-cholesterol and, noticeably, for those with lower baseline BMI (Figure 3). 
A recent meta-analysis [70] examined 13 clinical trials involving 365 participants who received 
diets supplemented with walnuts accounting for 5% to 25% of total energy and lasting 4–24 weeks. 
When compared with control diets, walnut-rich diets resulted in a significantly greater decrease in total 
and  LDL-cholesterol  concentrations,  with  weighted  mean  decreases  of  10.3  and  9.2  mg/dL, 
respectively. The overall result indicated that the walnut diets compared with the control diets were 
associated with a 6.7% greater decrease in LDL-cholesterol concentration, which concurs with the 
mean 7% decrease reported with various nut types in the pooled analysis [69]. HDL-cholesterol and 
triglycerides were not significantly affected by walnut diets more than by control diets. 
Recent well  controlled intervention studies with walnuts [71-74], almonds [75], hazelnuts [76], 
pistachios [77], macadamias [78], and peanuts [79] showed LDL-cholesterol reductions ranging from 
4% to 11% versus comparator diets, confirming the cholesterol-lowering efficacy of various nut types. 
A Mediterranean diet supplemented with 30 g of mixed nuts (walnuts, almonds and hazelnuts) per day 
also showed beneficial effects on the lipid profile compared with advice on a low-fat diet in diabetic 
and non diabetic participants in the PREDIMED study, a randomized trial of dietary intervention for 
the  primary  prevention  of  cardiovascular  disease  [80].  Of  note,  two  randomized  trials  that  used 
cashews or walnuts [81] and mixed nuts [82] compared to control diets in obese patients with the 
metabolic syndrome failed to show the predictable cholesterol lowering-effect, which supports the 
findings of the pooled analysis [69] (Figure 3) regarding the inverse association between cholesterol 
responses  to  nut  feeding  and  BMI.  There  may  be  a  mechanistic  explanation  for  decreased  lipid 
responsiveness to dietary intervention in patients with the metabolic syndrome. Studies have shown 
that the LDL cholesterol response to diets low in SFA [83] or to egg feeding as dietary cholesterol 
challenge [84] are blunted in obese, insulin-resistant subjects compared with lean, insulin-sensitive 
individuals. Prior studies had shown that higher BMI is associated with decreased LDL-cholesterol 
responses to hypolipidemic diets [85-87]. High cholesterol synthesis and reduced intestinal cholesterol Nutrients 2010, 2                                       
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absorption in insulin-resistant states [88,89] might explain these findings, as an enhanced cholesterol 
flux  through  the  liver  will  down-regulate  LDL  receptors  and  make  them  refractory  to  additional 
regulation by dietary fatty acid changes, while a decreased cholesterol flux though enterocytes would 
lessen both the cholesterol-raising response to dietary cholesterol and the cholesterol-lowering effect 
of  plant  sterols.  Nuts  are  rich  in  plant  sterols,  which  are  likely  to  contribute  to  their  cholesterol 
lowering effect [24], but this would be less operative when cholesterol absorption is low. 
Figure 3. LDL-cholesterol response to nut feeding by baseline LDL-cholesterol level and 
BMI. Data from a pooled study of 25 nut feeding trials (adapted from ref. 69). 
 
 
Nut consumption decreases total and LDL-cholesterol, but the response does not completely agree 
with that expected on the basis of the dietary fatty acid and cholesterol exchange between nut diets and 
control diets [90]. As discussed [19], the decrease in LDL-cholesterol by nut diets is greater than 
predicted in most studies. This suggests that nut constituents other than fatty acids, such as fiber and/or 
phytosterols [23,24] are also bioactive in lowering blood cholesterol. Recently suggestive evidence has 
been provided that phytosterols in nuts relate to the LDL-cholesterol response observed after their 
consumption [91]. 
4.2. Nuts, Insulin resistance and Glycemic Control 
Some interventional studies have examined the effects of nut-enriched diets on glycemic control in 
diabetic patients and insulin sensitivity in insulin-resistant states. Nuts had no discernible effect on 
fasting or postprandial glucose and hemoglobin A1C in patients with diabetes [73,92-94]. Changes in 
insulin sensitivity in response to nut diets have been inconsistent. No effects were seen in feeding 
studies of healthy subjects [92], hyperlipidemic patients [95], or patients with insulin-resistant states, 
such as obesity [96] or the metabolic syndrome [97,98]. Two recent small studies, however, found 
reduced insulin levels in patients with metabolic syndrome [82] and diabetes [73] after nut feeding. 
The three-month report of the larger PREDIMED study [80] also showed that the Mediterranean diet Nutrients 2010, 2                                       
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enriched with nuts was associated with improved insulin sensitivity and fasting glucose levels in non 
diabetic and diabetic participants, respectively.  Finally, two studies from the same group [99,100] 
reported reduced postprandial glucose and insulin excursions after almond meals compared with those 
elicited after meals containing carbohydrates with a high glycemic index. Thus, in spite of their high 
energy and fat load, nuts do not worsen and may even improve metabolic control or insulin sensitivity 
in insulin-resistant states, but more evidence is necessary. 
4.3. Effects of Nuts on Emerging Cardiovascular Risk Factors 
By  virtue  of  their  unique  fat  and  non-fat  composition,  nuts  are  likely  to  affect  markers  of 
atherogenesis other than the lipid profile or carbohydrate metabolism. More recently, the effects of 
nuts on novel CHD risk factors have been evaluated, including oxidative stress, inflammation and 
vascular reactivity, as reviewed [13,20-22]. The emerging picture is that frequent nut consumption has 
beneficial effects on cardiovascular risk factors beyond well-established cholesterol lowering. 
4.3.1. Oxidation 
Nuts are important sources of tocopherols and phenolic compounds with potent antioxidant effects, 
as shown by reduction of lipid peroxidation or oxidative DNA damage with nut extracts in studies in 
vitro  and  the  beneficial  effects  of  nut  intake  on  lipid  oxidation,  antioxidant  enzyme  activity,  and 
formation  of  cholesterol  oxidation  products  in  both  acute  and  chronic  experimental  animal 
studies [22,25]. Recently, walnuts were shown to contain substantial amounts of melatonin, which 
contributed a significant antioxidant effect in an experimental rat model [101]. In addition, because an 
important fraction of the fat contained in most nuts is made of MUFA, which is not a substrate for 
oxidation, enrichment of lipoprotein lipids with these fatty acids after nut consumption might decrease 
their susceptibility to oxidation. Nuts, especially walnuts, are also good sources of PUFA, and double 
bonds  in  the  molecular  structures  of  these  fatty  acids  are  preferred  initiation  sites  for  oxidation 
reactions  [102].  Consequently,  detrimental  changes  of  lipoprotein  oxidation  might  be  expected  to 
occur after walnut consumption unless counteracted by endogenous antioxidants in these nuts. 
Oxidative markers after feeding of MUFA-rich nuts, predominantly almonds, but also hazelnuts, 
peanuts, pistachios, macadamia nuts, cashews, pecans, and Brazil nuts, have been examined in several 
randomized  feeding  studies,  usually  of  small  size  and  lasting  from  three  to  eight  weeks,  as 
comprehensively reviewed up to 2008 [22]. Biomarkers of oxidation were secondary outcomes in most 
of these studies, which showed inconsistent results, with either reduced or unchanged oxidation, but in 
no case worse oxidative status, compared with various control diets. Several feeding studies of similar 
characteristics  have  assessed  oxidative  biomarkers  after  consumption  of  diets  supplemented  with 
PUFA-rich walnuts versus other healthy diets [reviewed in 21,22]. In general, there were no between-
diet differences in oxidative status, probably  because as discussed  antioxidants present in walnuts 
likely  prevented  the  potentially  adverse  effects  of  increasing  the  PUFA  content  of  
biological membranes. 
Four recent studies have assessed the acute effects of meals enriched with nuts on postprandial 
oxidation in comparison with nut-free meals [99,103-105]. Results have again been mixed, as two 
studies using walnuts [103] and almonds [104] had no discernible effect on oxidation biomarkers, Nutrients 2010, 2                                       
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while one study with almonds [99] and another study examining both almond and walnut meals [105] 
showed beneficial effects on postprandial oxidative stress. 
In a recent parallel feeding trial with higher statistical power than usual clinical studies with nuts, 
the PREDIMED study [106], a Mediterranean diet enriched with 30 g mixed nuts (half of it walnuts, 
the  rest  almonds  and  hazelnuts)  given  daily  for  12  weeks  to  subjects  at  high  cardiovascular  risk 
resulted in a lower oxidized LDL level compared with the control diet. Conversely, a smaller study 
using the same mixed-nut diet against a similar healthy diet without nuts for 12 weeks in patients with 
metabolic syndrome failed to show any between-diet differences in oxidized LDL and other oxidation 
biomarkers, except for reduced DNA damage with the nut diet [107]. 
In  summary,  available  evidence  from  clinical  studies  suggests  that  MUFA-rich  nuts  may 
moderately  improve  oxidative  status,  while  PUFA-rich  nuts  (walnuts)  have  a  neutral  or  slightly 
beneficial effect, but no studies have shown that frequent nut consumption reduces antioxidant defenses. 
4.3.2. Inflammation 
The high content of phenolic compounds in nuts, particularly in the pellicle, might anticipate an 
antiinflammatory  effect  of  frequent  nut  consumption  [108],  as  suggested  in  cross-sectional  
studies  [43-45].  Walnuts  could  be  predicted  to  be  more  antiinflammatory  than  other  nuts  for  two 
reasons. First, as discussed, walnuts are the only nuts that contain substantial amounts of ALA, which 
is described as one of the more anti-inflammatory fatty acids [109,110]. And second, walnuts are also 
particularly rich in the phenolic compound ellagic acid, which has shown potent anti-inflammatory 
properties in experimental studies [111,112]. Nevertheless, plasma levels of CRP, a standard measure 
of systemic low-grade inflammation, were usually unaffected in controlled feeding trials with almonds, 
walnuts, or mixed nuts, as reviewed up to 2008 [21]. On the other hand, other inflammatory mediators 
such as plasma levels of ICAM-1, vascular cell adhesion molecule [VCAM]-1, or IL-6 decreased after 
nut  diets  in  two  studies  [80,113].  It  must  be  noted  that  inflammatory  biomarkers  were  always 
secondary  outcomes  of  nut-feeding  trials,  thus  problems  of  statistical  power  to  detect  significant 
changes  are  a  problem.  The  same  can  be  said  of  a  recent  small  interventional  study  using  diets 
enriched with two doses of almonds versus a  healthy, nut-free diet [114]. However, in this study 
almond diets were superior to the control diet to reduce circulating CRP and also E-selectin, another 
potent inflammatory cytokine, but not IL-6. 
Two  recent  studies  have  examined  the  acute  effects  of  walnut-rich  meals  on  postprandial 
inflammation [103,115]. The study of Cortés et al. [103] compared high-SFA meals supplemented 
with either walnuts or olive oil on postprandial events in healthy and hypercholesterolemic subjects 
and found that postprandial rises of inflammatory markers were similarly blunted after the two meals, 
except for soluble E-selectin, which was lower after the walnut meal than after the olive oil meal. 
Jiménez-Gómez et al. [115] used meals enriched with walnuts, olive oil and butter in healthy subjects 
and found similar reductions in postprandial levels of circulating inflammatory biomarkers with the 
walnut  and  olive  oil  meals  compared  with  the  SFA-meal.  However,  these  authors  also  examined 
mRNA  expression  of  some  inflammatory  cytokines  in  circulating  blood  mononuclear  cells  and 
reported that the walnut meal elicited a reduced expression of IL-6 compared to the other two meals [115]. 
A  further  sub-study  of  the  PREDIMED  trial  analyzed  both  three-month  changes  in  circulating 
inflammatory biomarkers and in the expression of ligands for inflammatory molecules in circulating Nutrients 2010, 2                                       
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monocytes after the study diets, one of which was supplemented with ≈1-oz (30 g) mixed nuts per day [116]. 
The findings indicate reductions in both soluble ICAM-1 and IL-6 and, importantly, reduced monocyte 
expression  of  pro-inflammatory  ligands  after  the  walnut-rich  mixed  nut  diet  compared  with  the  
low-fat diet. 
In conclusion, nut consumption appears to have little effect on CRP but it evokes a reduction in 
concentrations of other inflammatory biomarkers. The gaps in our knowledge of the anti-inflammatory 
effects of nuts from clinical studies using enriched diets probably stem from the fact that most of them 
were not designed to evaluate this specific outcome. More recent studies of the effects of nut diets and 
nut  meals  on  postprandial  events  and  expression  of  pro-inflammatory  molecules  in  circulating 
mononuclear  cells  support  a  stronger  beneficial  effect  for  walnuts  while  beginning  to  unravel  the 
molecular bases for the anti-inflammatory effects of nut consumption. Nevertheless, more studies are 
warranted to conclusively resolve the important question of the antiinflammatory effects of nuts. 
4.3.3. Vascular reactivity 
Endothelial dysfunction is a critical event in atherogenesis that is implicated both in early disease 
and  in  advanced  atherosclerosis,  where  it  relates  to  perfusion  abnormalities  and  the  causation  of 
ischemic events [117]. It is characterized by a decreased bioavailability of the endogenous vasodilator 
NO,  synthesized  from  L-arginine  as  discussed  earlier  [29],  and  increased  expression  of 
proinflammatory  cytokines  and  cellular  adhesion  molecules.  Endothelial  injury  caused  by 
cardiovascular  risk  factors  or  atherosclerotic  vascular  disease  reduces  NO  production  and  this  is 
followed by arterial wall abnormalities, both functional [inhibition of vasodilatation or paradoxical 
vasoconstriction]  and  structural  [smooth  muscle  cell  growth  and  blood  cell  adhesion]  that  are 
responsible for the initiation, development, and progression of atherosclerosis [117]. 
It has been known for some time that food intake affects vascular reactivity. Short-term feeding 
studies  have  consistently  shown  that  diets  rich  in  SFA  impair  endothelial  function  [118-120].  In 
addition, a single fatty meal rich in SFA usually is followed by transient endothelial dysfunction in 
association  with  elevated  triglyceride-rich  lipoproteins  [121].  Whether  acute  or  chronic,  these 
detrimental  effects  can  be  counteracted  by  the  administration  of  healthy  nutrients,  such  as  n-3  
PUFA [120], antioxidant vitamins and phenolic compounds [122,123], and L-arginine [124], all of 
them  nut  constituents.  Thus,  it  could  be  predicted  that  nut  consumption  could  beneficially  influence 
endothelial function. 
Walnut  diets  have  been  examined  versus  control  diets  in  three  randomized  crossover  
studies  [74,103,113]  by  using  the  standard  method  for  noninvasive  assessment  of  conduit  artery 
endothelial  function,  flow-mediated  dilatation  (FMD)  in  the  brachial  artery  [117].  The  first  study 
showed that, by comparison with an isoenergetic Mediterranean diet with similar SFA content, a four-
week walnut diet attenuated the endothelial dysfunction associated with hypercholesterolemia [113]. In 
a follow-up of this trial, it was shown that adding walnuts to a high-fat, high-SFA meal counteracted 
ensuing postprandial endothelial dysfunction compared to the same meal with added olive oil [103]. 
The third study, conducted in diabetic patients, compared a walnut diet with an isoenergetic ad libitum 
diet  with  similar  SFA  content  but  without  walnuts,  each  lasting  eight  weeks,  and  confirmed  that 
walnuts improve FMD [74]. By analogy with the improvement of endothelial function observed after 
supplementation of marine n-3 PUFA [118-120], this beneficial effect of walnuts may be ascribed in Nutrients 2010, 2                                       
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part to their high ALA content. Antioxidants and L-arginine also might have played a role. Of note, 
supplementing  a  high-fat  meal  with  ALA  from  canola  oil  was  also  associated  with  improved 
postprandial endothelial function in patients with diabetes [125]. 
Two further studies have assessed the effects of nuts on vascular reactivity [107,126]. A recent 
study from Turkey reported improved FMD after a diet supplemented with pistachios compared with a 
healthy diet, but the sequential design of the interventions precludes firm conclusions [126]. Finally, a 
12-week parallel design study in patients with metabolic syndrome comparing healthy diets with or 
without  supplementation  with  30  g  of  mixed  nuts  per  day  found  no  between-diet  differences  in 
vascular reactivity, as assessed by digital pulse amplitude tonometry [107]. However, it must be noted 
that  this is  a  non-standard  technique  to  measure  endothelial  function  with  much  less  clinical  trial 
experience than FMD of the brachial artery [117].  
In summary, there is consisting evidence from two studies that walnut diets improve FMD and from 
another  study  that  this  effect  can  be  observed  after  a  single  walnut  meal.  In  support  of  these 
observations, Davis et al. [127] showed that walnut feeding also reduced the expression of endothelin-1, 
a potent endothelial activator, in an animal model of accelerated atherosclerosis, and this effect was 
attributable to the fat component of walnuts. Although there is a paucity of vascular reactivity studies 
after consumption of diets enriched with nuts other than walnuts, they might be expected to show 
similar beneficial effects because, with the exception of ALA, particular to walnuts, all nuts contain 
substantial quantities of bioactive compounds that can favorably influence vascular reactivity. This is a 
key area for future research. 
When endothelial function improves, a lower blood pressure could be predicted. This has not been 
observed in the usually small-sized clinical studies performed to date, but the larger PREDIMED trial 
did show significant reductions in both systolic and diastolic blood pressure after the nut-supplemented 
Mediterranean  diet  compared  with  the  control  diet  [80].  A  recent  report  of  the  PREDIMED  trial 
provides an insight into the possible mechanism of this antihypertensive effect by showing that the nut 
diet was associated with reduced cholesterol: phospholipid ratios of erythrocyte membranes, which 
would  translate  into  an  increase  of  membrane  fluidity  [128].  Possibly  future  adequately  powered 
studies  might  uncover  a  true  antihypertensive  effect  of  nut  intake.  As  discussed,  there  is  also 
insufficient  evidence  from  prospective  studies  of  the  relationship  between  nut  consumption  and 
hypertension  [50,51].  Further  epidemiological  and  clinical  studies  on  this  important  topic  are  
clearly needed. 
5. Safety of Nut Consumption 
There are two main concerns regarding the safety of increasing nut consumption: possible weight 
gain (and worsening metabolic complications of increased adiposity, such as the metabolic syndrome 
and diabetes) and allergic reactions. While the first can reasonably be dispelled, the second merits 
attention in particular situations. An additional concern is potential toxicity through contamination of 
nuts with mycotoxins, particularly aflatoxins, which is a problem that affects agricultural economies 
and is beyond the scope of this review [reviewed in 129,130]. 
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5.1. Body Weight 
The common perception that fatty foods provide excess energy and thus promote obesity has had a 
negative  effect  on  the  image  of  nuts.  The  question  of  whether  increasing  the  intake  of  nuts  and 
therefore calories could lead to unwanted weight gain and related health problems is a critical one. 
However, as thoroughly reviewed [13,16,26,27], there is considerable scientific evidence indicating 
that there are no adverse effects of frequent nut consumption on energy balance or body weight. Some 
studies suggest that nut consumption might even help lose weight. 
First, the epidemiological studies that related the frequency of nut consumption with a reduction of 
incident CHD [1,39-41] or diabetes [46] showed a neutral or even inverse association between nut 
intake and BMI. Recent reports from two large prospective cohorts [131,132] and a cross-sectional 
study [133] support these findings. In a 28-month prospective study of the SUN cohort conducted in 
Spain in 8865 university graduates, a significant inverse association between nut consumption and 
weight gain was reported. Compared with those who never or almost never ate nuts, participants who 
ate nuts ≥2 times/wk had a 31% lower risk of gaining ≥5 kg during follow-up, while participants who 
frequently consumed nuts had an average 0.42 kg less weight gain than did those who rarely consumed 
nuts after multivariate adjustment [131]. The Nurses’ Health Study followed 51,188 women for eight 
years and showed that women who reported eating nuts ≥2 times/wk had 0.4 kg less mean weight gain 
than did women who rarely ate nuts, a small but significant difference. The results were similar for tree 
nuts  and  peanuts  in  normal-weight,  overweight,  and  obese  participants.  In  multivariate  analyses, 
greater  nut  consumption  (≥2  times/wk  compared  with  never/almost  never)  was  associated  with  a 
slightly lower risk of obesity, with a hazard ratio of 0.77 (CI, 0.57 to 1.02) [132]. In a cross-sectional 
study of a sample of 847 subjects recruited into the PREDIMED study, nut consumption was inversely 
associated with adiposity measures (BMI and waist circumference) independently of other lifestyle 
variables. From regression coefficients of nut intake versus adiposity variables, it was predicted that 
BMI and waist circumference decreased by 0.78 kg/m
2 and 2.1 cm, respectively, for each serving of 30 g of 
nuts [133]. 
Second, the nut intervention trials with outcomes on lipid changes that were carried out in free-
living individuals showed no weight gain or a tendency to lose weight in those assigned to nut diets 
compared with control diets, as reviewed [26,27]. A similar lack of weight gain was documented in the 
mostly overweight or obese participants in the PREDIMED study who consumed 30 g of mixed nuts 
per day during three months [80] and in overweight diabetics consuming 30 g of walnuts for six 
months in a study from Australia [94]. Recent evidence from the PREDIMED study shows a decreased 
prevalence of the metabolic syndrome, mainly due to reduced visceral adiposity, after intervention for 
12  months  in  participants  following  a  Mediterranean  diet  supplemented  with  30  g  of  nuts  
per day [134]. 
Third, four clinical studies specifically investigated the effects on body weight of supplementing the 
customary diets of free-living subjects with nuts without constraints on energy balance [135-138]. In 
these studies, sizeable quantities of peanuts, almonds or walnuts were provided for daily consumption 
during periods ranging from eight weeks to six months, without advice on how to include them in their 
diet. Compared with the corresponding control diet periods, there were insignificant increases or no 
changes in body weight after the nut diets in all these studies. Nutrients 2010, 2                                       
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Finally, two clinical trials have assessed the efficacy of low-calorie diets with added nuts versus 
conventional low-fat diets for weight loss, and the results showed the nut diets resulting in superior 
long-term participation and adherence, with consequent improvements in weight loss [139,140]. 
There are potential mechanisms for the lack of a weight-promoting effect or even a tendency to 
reduce adiposity of nut consumption in spite of increased energy acquisition. Probably because nuts 
are fatty foods containing substantial amounts of fiber, their chronic consumption in a free feeding 
situation causes satiation and elicits a strong dietary compensation, whereby intake of other energy-
dense  foods  is  curtailed,  which  accounts  for  roughly  two  thirds  of  the  energy  derived  from  
nuts [135,141]. Increased satiation subsequent to nut consumption has been more difficult to detect in 
acute studies [98,142]. An enhanced thermogenic effect of nut intake was also postulated based on 
findings from a 19-week feeding trial with peanuts (88 g/day) in healthy subjects, who showed an 11% 
increase in resting energy expenditure [136]. These findings could not be reproduced in acute studies 
with walnuts [98,142]. Fat malabsorption, documented during nut diets as increased fecal fat excretion, 
also can contribute to the lack of weight gain. Increased stool fat losses may be due in part to the high 
fiber  content  of  nuts  [23]  or  to  incomplete  digestion  of  their  matrices  because  the  fat  of  nuts  is 
enclosed within cell membranes, which are not readily available to digestive enzymes [143], an effect 
that can be compounded by incomplete mastication [144]. At any rate, the satiating effect of nuts with 
subsequent food compensation appears to be the main reason for their lack of weight-promoting effect. 
5.2. Allergic Reactions 
Nuts are a well known cause of food allergy, with estimated prevalence rates of approximately 1% 
in the general population [reviewed in 145]. A recent systematic review of population-based studies 
points  to  a  prevalence  of  4.3%  when  diagnosis  is  based  on  food  challenge  tests  and  <1%  when 
sensitization is assessed by skin prick test [146]. Allergic reactions to nuts are due to allergenic seed 
storage proteins that elicit specific IgE antibodies. They affect principally young children and may be 
particularly severe, even life-threatening. Indeed, fatal anaphylactic reactions following nut ingestion 
have been documented. Severity of coexisting atopic diseases [asthma, rhinitis, and eczema] predicts 
which patients are most likely to develop life-threatening allergic reactions to tree nuts and peanuts [147]. 
A minority of children with peanut allergy developed tolerance with time. Once nut allergy is firmly 
established, prevention of subsequent episodes, which tend to be clinically worse, includes patient and 
family education to avoid all types of nuts and be careful of hidden nut products in processed foods. 
Patients and relatives must be instructed on how to recognize early symptoms of an allergic reaction 
and how to treat promptly an anaphylactic episode. 
6. Conclusion 
Nuts are energy dense foods rich in bioactive macronutrients, micronutrients and phytochemicals. 
The  unique  composition  of  nuts  is  critical  for  their  health  effects.  Indeed,  there  are  consistent 
evidences from epidemiologic and clinical studies of the beneficial effects of nut consumption on risk 
of CHD, including sudden cardiac death, as well as on diabetes in women, and on major and emerging 
cardiovascular risk factors, as summarized in Table 3. Nutrients 2010, 2                                       
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Table  3.  The  effect  of  nut  consumption  on  cardiovascular  risk  factors.  Summary  of 
scientific evidence. 
Variables  Effect  Level of evidence 
Epidemiologic studies     
Coronary heart disease  Decrease  ++ 
Sudden cardiac death  Decrease  + 
Ischemic stroke  No change  + 
Heart failure  No change  + 
Hypertension  Decrease  +/- 
Diabetes  No change/decrease  +/- 
Cancer   No change/decrease  +/- 
Gallstone disease  Decrease  + 
Complications of diverticular disease  Decrease  + 
Inflammatory markers  Decrease  + 
Body weight  No change/decrease  ++ 
Clinical studies     
Blood cholesterol  Decrease  ++ 
Insulin sensitivity  No change/increase  +/- 
Blood pressure  Decrease  + 
Oxidation  No change/decrease  +/- 
Inflammation  No change/decrease  +/- 
Vascular reactivity  Increase  + 
Body weight  No change  ++ 
Visceral adiposity  Decrease  + 
+/-, equivocal evidence; 
+, limited evidence from few studies; 
++, consisting evidence in several studies. 
 
The evidence to date is convincing that including nuts in a healthy dietary pattern will extend the 
cardioprotective effects beyond those attributable to the components of any healthy diet exclusive of nuts. 
Importantly, these effects take place without undue weight gain, or even with reduced adiposity, and 
target multiple cardiovascular risk factors and mechanisms, which help explain why nuts so potently 
reduce  the  risk  for  CHD.  There  is  also  emerging  evidence  from  acute  studies  that  single  meals 
enriched with nuts can have a beneficial impact on postprandial events related to atherogenesis, such 
as  glucose  and  triglyceride  raises,  inflammation,  and  endothelial  activation.  Understanding  the 
underlying biological mechanisms of the effects of nuts on mediators of CHD, obesity, metabolic 
syndrome, diabetes, and cancer should help in the design of diets that include nuts to maximally reduce 
chronic disease risk. The vegetarian, Mediterranean, and many Asian diets are traditional plant-based 
dietary patterns that include nuts and are reputed for their beneficial effects on health. 
A healthy dietary pattern is high in vegetables, fruits, legumes, nuts, whole grains, and lean protein 
sources and low-fat dairy products [10]. Nuts are a popular and important source of unsaturated fat and 
high-quality vegetable protein in vegetarian diets, where they  rank high on the list of foods most 
frequently consumed, above meat substitutes [9,148]. The optimal nutrient composition of nuts and the 
impressive evidence gained from epidemiologic and clinical studies on their health benefits indicates Nutrients 2010, 2                                       
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that they are an indispensable contribution to a well-balanced vegetarian diet. Also, knowledge has 
accumulated that dietary patterns close to the Mediterranean diet, in which nuts are a key food item, 
are  associated  with  many  beneficial  health  outcomes  [16,149].  Indeed  both  exposure  to  the 
Mediterranean diet and frequency of nut consumption are among the dietary factors with stronger 
evidences for a causal link with CHD prevention [150]. Ongoing research like the large randomized 
PREDIMED trial, wherein one daily serving of mixed nuts within the context of the Mediterranean 
diet is provided to participants at high cardiovascular risk in one arm of this six-year study [80], might 
eventually settle the critical issues of whether, in comparison with a healthy control diet without nuts, a 
healthy  diet  supplemented  with  one  daily  serving  of  nuts  prevents  cardiovascular  events  and 
development  of  other  prevalent  chronic  disorders,  including  diabetes,  cancer  and  
neurodegenerative diseases. 
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